Global Recurrent Glioblastoma Multiforme Treatment Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Recurrent Glioblastoma Multiforme Treatment

• 1.1 Definition of Recurrent Glioblastoma Multiforme Treatment
• 1.2 Recurrent Glioblastoma Multiforme Treatment Segment by Type
  • 1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 AU-105
  • 1.2.3 Axitinib
  • 1.2.4 AXL-1717
  • 1.2.5 AZD-7451
  • 1.2.6 Others
• 1.3 Recurrent Glioblastoma Multiforme Treatment Segment by Applications
  • 1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Others
• 1.4 Global Recurrent Glioblastoma Multiforme Treatment Overall Market
  • 1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue (2014-2025)
  • 1.4.2 Global Recurrent Glioblastoma Multiforme Treatment Production (2014-2025)
  • 1.4.3 North America Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)
  • 1.4.4 Europe Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)
  • 1.4.5 China Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)
  • 1.4.6 Japan Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)
  • 1.4.8 India Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Recurrent Glioblastoma Multiforme Treatment
• 2.3 Manufacturing Process Analysis of Recurrent Glioblastoma Multiforme Treatment
• 2.4 Industry Chain Structure of Recurrent Glioblastoma Multiforme Treatment

3 Development and Manufacturing Plants Analysis of Recurrent Glioblastoma Multiforme Treatment

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Recurrent Glioblastoma Multiforme Treatment Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Recurrent Glioblastoma Multiforme Treatment
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Recurrent Glioblastoma Multiforme Treatment Production and Capacity Analysis
• 4.2 Recurrent Glioblastoma Multiforme Treatment Revenue Analysis
• 4.3 Recurrent Glioblastoma Multiforme Treatment Price Analysis
• 4.4 Market Concentration Degree

5 Recurrent Glioblastoma Multiforme Treatment Regional Market Analysis

• 5.1 Recurrent Glioblastoma Multiforme Treatment Production by Regions
  • 5.1.1 Global Recurrent Glioblastoma Multiforme Treatment Production by Regions
  • 5.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Regions
• 5.2 Recurrent Glioblastoma Multiforme Treatment Consumption by Regions
• 5.3 North America Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.3.1 North America Recurrent Glioblastoma Multiforme Treatment Production
  • 5.3.2 North America Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Recurrent Glioblastoma Multiforme Treatment Import and Export
• 5.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.4.1 Europe Recurrent Glioblastoma Multiforme Treatment Production
  • 5.4.2 Europe Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Recurrent Glioblastoma Multiforme Treatment Import and Export
• 5.5 China Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.5.1 China Recurrent Glioblastoma Multiforme Treatment Production
  • 5.5.2 China Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Recurrent Glioblastoma Multiforme Treatment Import and Export
• 5.6 Japan Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.6.1 Japan Recurrent Glioblastoma Multiforme Treatment Production
  • 5.6.2 Japan Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Recurrent Glioblastoma Multiforme Treatment Import and Export
• 5.7 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.7.1 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Production
  • 5.7.2 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Import and Export
• 5.8 India Recurrent Glioblastoma Multiforme Treatment Market Analysis
  • 5.8.1 India Recurrent Glioblastoma Multiforme Treatment Production
  • 5.8.2 India Recurrent Glioblastoma Multiforme Treatment Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Recurrent Glioblastoma Multiforme Treatment Import and Export

6 Recurrent Glioblastoma Multiforme Treatment Segment Market Analysis (by Type)

• 6.1 Global Recurrent Glioblastoma Multiforme Treatment Production by Type
• 6.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Type
• 6.3 Recurrent Glioblastoma Multiforme Treatment Price by Type

7 Recurrent Glioblastoma Multiforme Treatment Segment Market Analysis (by Application)

• 7.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption by Application
• 7.2 Global Recurrent Glioblastoma Multiforme Treatment Consumption Market Share by Application (2014-2019)

8 Recurrent Glioblastoma Multiforme Treatment Major Manufacturers Analysis

• 8.1 Boehringer Ingelheim GmbH
  • 8.1.1 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.1.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
  • 8.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Boston Biomedical, Inc.
  • 8.2.1 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.2.2 Boston Biomedical, Inc. Product Introduction, Application and Specification
  • 8.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Bristol-Myers Squibb Company
  • 8.3.1 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.3.2 Bristol-Myers Squibb Company Product Introduction, Application and Specification
  • 8.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Cantex Pharmaceuticals, Inc.
  • 8.4.1 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.4.2 Cantex Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Cavion LLC
  • 8.5.1 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.5.2 Cavion LLC Product Introduction, Application and Specification
  • 8.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Celldex Therapeutics, Inc.
  • 8.6.1 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.6.2 Celldex Therapeutics, Inc. Product Introduction, Application and Specification
  • 8.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Coherus BioSciences, Inc.
  • 8.7.1 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.7.2 Coherus BioSciences, Inc. Product Introduction, Application and Specification
  • 8.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Cortice Biosciences, Inc.
  • 8.8.1 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.8.2 Cortice Biosciences, Inc. Product Introduction, Application and Specification
  • 8.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Eisai
  • 8.9.1 Eisai Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.9.2 Eisai Product Introduction, Application and Specification
  • 8.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Eli Lilly and Company
  • 8.10.1 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
  • 8.10.2 Eli Lilly and Company Product Introduction, Application and Specification
  • 8.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 EnGeneIC Ltd
• 8.12 ERC Belgium SA
• 8.13 GenSpera, Inc.
• 8.14 Genzyme Corporation
• 8.15 GW Pharmaceuticals Plc
• 8.16 ImmunoCellular Therapeutics, Ltd.

9 Development Trend of Analysis of Recurrent Glioblastoma Multiforme Treatment Market

• 9.1 Global Recurrent Glioblastoma Multiforme Treatment Market Trend Analysis
  • 9.1.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Recurrent Glioblastoma Multiforme Treatment Regional Market Trend
  • 9.2.1 North America Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
  • 9.2.2 Europe Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
  • 9.2.3 China Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
  • 9.2.4 Japan Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
  • 9.2.5 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
  • 9.2.6 India Recurrent Glioblastoma Multiforme Treatment Forecast 2019-2025
• 9.3 Recurrent Glioblastoma Multiforme Treatment Market Trend (Product Type)
• 9.4 Recurrent Glioblastoma Multiforme Treatment Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Recurrent Glioblastoma Multiforme Treatment Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List